MediWound Ltd.

NASDAQ:MDWD

Biotechnology

Healthcare
$13.61 -0.60%

-$0.09 today

Market cap
$175.71M
Beta
0.15
P/E (TTM)
-7.0
EPS (TTM)
-$2.03
52W Low $13.54High $21.26

Volume 0.17M

Average 0.09M

MDWD Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

MediWound Ltd.NASDAQ: MDWD

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $644K fell 23.7% year over year, behind the -16.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 2.7% from the prior quarter. Over 3 fiscal years it compounded at +16.9% a year.

Context

  • Stock-based compensation amounted to 18.3% of revenue in FY2025, up 2.8 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -23.7% toward the trailing-twelve-month pace of -16.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$644K-2.7% QoQ
Last fiscal yearDec 2025
$3.11M-1.0% YoY
LTMMar 2026
$2.91M-16.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.7%——
1 year-1.0%——
3-year CAGR+16.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
3.11M USD
Year-over-year change
-1.0%
4-year CAGR
+16.7%

Stock-Based Compensation vs competitors

How MDWD compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -16.2% is the 7th highest of 9, against a peer median of +26.5%.
  • Stock-based compensation amounts to 20.1% of revenue for MDWD, versus a peer median of 312.1%.
MDWD Competitors
Stock-Based Compensation for MDWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$15.21M USD———
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$11.86M USD+7.9%+52.0%36.3%
IVVDInvivyd, Inc.LTM Mar 2026$11.51M USD-33.2%-18.7%20.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$10.44M USD+36.3%-2.0%587.9%
TARAProtara Therapeutics, Inc.LTM Mar 2026$4.36M USD+16.7%-17.0%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$4.19M USD+122.7%+4.3%—
MDWDMediWound Ltd.LTM Mar 2026$2.91M USD-16.2%+16.9%20.1%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$2.64M USD+336.0%+112.4%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$1.44M USD-63.8%——
Peer median (excluding MDWD) —+26.5%+4.3%312.1%

Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.55M)(19.6M)(6.72M)(30.22M)(23.88M)
Depreciation & Amortization1.24M1.27M1.3M1.48M1.71M
Deferred Income Tax(124K)0000
Stock-Based Compensation1.67M1.95M1.94M3.14M3.11M
Change in Working Capital162K(7.24M)2.34M1.27M4.77M
Accounts Receivables929K(7.58M)4.76M(1.02M)4.88M
Inventory257K(721K)(906K)187K(1.36M)
Accounts Payables1.72M414K(594K)406K2.35M
Other Working Capital(2.75M)645K(928K)1.7M(1.1M)
Other Non-Cash Items1.69M11.74M(9.33M)10.71M(236K)
Operating Cash Flow(8.92M)(11.89M)(10.47M)(13.62M)(14.53M)
Capital Expenditures(489K)(555K)(6.46M)(6.27M)(5.51M)
Acquisitions (Net)00000
Purchases of Investments0000(14.04M)
Sales of Investments4M0000
Other Investing Activities35K74K(27.86M)(2.12M)0
Investing Cash Flow3.55M(481K)(34.32M)(8.4M)(19.54M)
Debt Repayment000(928K)0
Common Stock Issued3K38.38M24.91M22.17M31.05M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.05M)(2.62M)(1.99M)(1.84M)(1.43M)
Financing Cash Flow(1.05M)35.76M22.92M19.39M29.62M
Effect of Forex Changes88K(549K)(160K)(84K)95K
Net Change in Cash(6.33M)22.85M(22.03M)(2.71M)(4.36M)
Free Cash Flow(9.41M)(12.44M)(16.93M)(19.9M)(20.04M)

MediWound Ltd.

NASDAQ:MDWD

Intrinsic Alpha fair value

Locked

Current Price

$13.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.